Prostate Tissue BioBank

Abramson Cancer Center at Penn Medicine200 enrolled

Overview

Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. The investigators have shown that 5% of men diagnosed with prostate cancer localized to their prostate gland and up to 10-15% of patients with metastatic prostate cancer gland are carriers of an inherited gene mutation. The Prostate Tissue BioBank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline DNA from pathogenic mutation carriers in addition to age-matched control samples. Our primary goal is to investigate prostate cancer development and treatment response in carriers of germline DNA repair mutations, as compared to non-carrier controls.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Prostate Cancer Genetic Predisposition

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Carriers (Group 1): 1. Confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene. 2. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer Controls (Group 2): 1\. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer Exclusion Criteria: * N/A

Outcomes

Primary Outcomes

Clinical and pathological data for patients with prostate tissue samples

Data will be collected on consented patients who undergo prostate biopsy, prostatectomy or metastatic biopsy.

Time frame: 5 years